Literature DB >> 15001914

Benefits of resection for metachronous lung cancer.

Richard J Battafarano1, Seth D Force, Bryan F Meyers, Jennifer Bell, Tracey J Guthrie, Joel D Cooper, G Alexander Patterson.   

Abstract

OBJECTIVES: The benefits of resection for metachronous lung cancer are not well described. The objective of this study was to evaluate the safety and efficacy of surgical resection for metachronous lung cancers.
METHODS: We reviewed the charts of all patients who underwent a second resection for a metachronous lung cancer from July 1, 1988, to December 31, 2002. Type of resection, operative morbidity, mortality, and survival by stage were analyzed. Survival was determined by using the Kaplan-Meier survival method. All patients were pathologically staged by using the 1997 American Joint Committee on Cancer standards.
RESULTS: Pulmonary resections were performed in 69 patients who had undergone a previous resection. The mean interval between the first and second resection was 2.4 +/- 2.5 years. Seventy-three percent of patients presented with stage I cancers, 9% with stage II cancers, and 17% with stage III cancers. Lobectomy and wedge resection were performed with equal frequency (42% each) for the metachronous cancers. Operative mortality for the second resection was 5.8%. The mean follow-up after the second resection was 37 months. Overall 5-year actuarial survival for the entire group after the second resection was 33.4%.
CONCLUSIONS: Operations for metachronous cancers provided survival that approximated the expected survival for lung cancer. Surgical intervention should be considered as a safe and effective treatment for resectable metachronous lung cancer in patients with adequate physiologic pulmonary reserve.

Entities:  

Mesh:

Year:  2004        PMID: 15001914     DOI: 10.1016/j.jtcvs.2003.08.055

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  17 in total

1.  Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity.

Authors:  Alessandro Testolin; Maria Silvia Favretto; Stefania Cora; Carlo Cavedon
Journal:  Br J Radiol       Date:  2015-08-20       Impact factor: 3.039

2.  Metachronous second primary lung cancer surgically treated five years or more after the initial surgery.

Authors:  Satoshi Koezuka; Yoshinobu Hata; Hajime Otsuka; Takashi Makino; Naobumi Tochigi; Kazutoshi Shibuya; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2015-07-01

Review 3.  Clinicopathological characteristics of colorectal metastases from lung cancer: systematic review of the case reports in the Japanese literature.

Authors:  Yoshinori Kikuchi; Hideaki Shimada; Kazutoshi Isobe; Ryo Shimizu; Munehiro Wakabayashi; Kazuhisa Yamaguchi; Yoshinori Igarashi
Journal:  Int Cancer Conf J       Date:  2021-07-19

4.  Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.

Authors:  R Taylor Ripley; Robert R McMillan; Camelia S Sima; Saad M Hasan; Usman Ahmad; Feiran Lou; David R Jones; Valerie W Rusch; Nabil P Rizk; James Huang
Journal:  Ann Thorac Surg       Date:  2014-07-16       Impact factor: 4.330

5.  Prognostic Impact of Tumor Doubling Time in Patients with Metachronous Lung Cancer.

Authors:  Keisuke Asakura; Yukihiro Yoshida; Hiroyuki Sakurai; Kazuo Nakagawa; Noriko Motoi; Shun-Ichi Watanabe
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

6.  Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma.

Authors:  Akira Iyoda; Shi-Xu Jiang; William D Travis; Naomi Kurouzu; Fumihiro Ogawa; Hideki Amano; Yuichi Sato; Valerie W Rusch; Makoto Saegusa; Yukitoshi Satoh
Journal:  Mol Clin Oncol       Date:  2013-02-28

7.  Prior Treatment for Non-small Cell Lung Cancer Is Associated With Improved Survival in Patients who Undergo Definitive Stereotactic Body Radiation Therapy for a Subsequent Lung Malignancy: A Retrospective Multivariate and Matched Pair Analysis.

Authors:  Mark K Farrugia; Sung Jun Ma; Mark W Hennon; Chukwumere E Nwogu; Elisabeth U Dexter; Anthony L Picone; Todd L Demmy; Jorge A Gomez-Suescun; Simon Fung-Kee-Fung; Sai S Yendamuri; Anurag K Singh
Journal:  Am J Clin Oncol       Date:  2021-01-01       Impact factor: 2.339

8.  Predicting the Mortality Benefit of CT Screening for Second Lung Cancer in a High-Risk Population.

Authors:  C Matthew Kinsey; Katharine L Hamlington; Jacqueline O'Toole; Renee Stapleton; Jason H T Bates
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

9.  Unusual synchronous lung tumors: mucoepidermoid carcinoma and mucinous adenocarcinoma.

Authors:  Ana M Ponea; Creticus P Marak; Ying Sun; Achuta Kumar Guddati; Amit S Tibb
Journal:  Case Rep Oncol Med       Date:  2014-02-18

10.  Triple synchronous primary lung cancer: a case report and review of the literature.

Authors:  Muhammad Kashif; Puvanalingam Ayyadurai; Luong Thanha; Misbahuddin Khaja
Journal:  J Med Case Rep       Date:  2017-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.